345 related articles for article (PubMed ID: 23420490)
21. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
22. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
25. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
26. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
27. Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL.
Kassem A; Lindholm C; Lerner UH
PLoS One; 2016; 11(6):e0156708. PubMed ID: 27311019
[TBL] [Abstract][Full Text] [Related]
28. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3.
Choi B; Lee EJ; Shin MK; Park YS; Ryu MH; Kim SM; Kim EY; Lee HK; Chang EJ
Oncotarget; 2016 Aug; 7(34):55506-55517. PubMed ID: 27458153
[TBL] [Abstract][Full Text] [Related]
31. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
33. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
34. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
35. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
[TBL] [Abstract][Full Text] [Related]
36. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD; Dougall WC
Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
[TBL] [Abstract][Full Text] [Related]
37. [Expression and significance of brain-derived neurotrophic factors and receptors in multiple myeloma].
Sun CY; Hu Y; Wu T; Wang YD; He WJ
Zhonghua Nei Ke Za Zhi; 2005 Dec; 44(12):906-9. PubMed ID: 16409727
[TBL] [Abstract][Full Text] [Related]
38. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
39. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
[TBL] [Abstract][Full Text] [Related]
40. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]